Cardiogenic Shock
V1.1.2. March 18, 2023
Definitions of Cardiogenic Shock (1)
Management
ESC 2021 versus AHA 2017 algorithms.
I. ESC 2021 (2)
Management of patients with cardiogenic shock
II. AHA 2017 (1)
Cardiogenic Shock Management Pathway
Recommendations for the initial treatment of acute heart failure (2)
Section considering pharmacological interventions. Columns to the right are Class of Recommendation and Level of Evidence.
Vasopressors and inotropes summary tables of ESC and AHA guidelines
They have slight differences in dosage ranges for some drugs.
I. Inotropes and/or vasopressors used to treat acute heart failure (2)
Mechanism of action and hemodynamic effects of common vasoactive medications in cardiogenic shock (1)
Related drugs
Vasopressors
Dopamine
Phenylephrine
Vasopressine
Inodilators
Isoproterenol
Milrinone
Enoximone
Levosimendan
References
van Diepen S, Katz JN, Albert NM, et al. Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association. Circulation. 2017;136(16):e232-e268. doi:10.1161/CIR.0000000000000525
Circulation (Open Access)McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [published correction appears in Eur Heart J. 2021 Oct 14;:]. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368
European Society of Cardiology (Open Access)urheartj/ehaa612
European Heart Journal (Open Access)
Further reading
Moskovitz JB, Levy ZD, Slesinger TL. Cardiogenic Shock. Emerg Med Clin North Am. 2015;33(3):645-652. doi:10.1016/j.emc.2015.04.013
PubmedHelman A. A Simplified Approach to Cardiogenic Shock. ACEP Now. 2022. Accessed March 19, 2023.
ACEPNow (Open Access)
® 2023 EMDrugs. All rights reserved.
contact@emdrugs.com
DISCLAIMER
⚠ This website provides general information and discussion about medications, health, and related subjects. The words and other content provided in this website, and in any linked materials, are not intended and should not be construed as medical advice. If the reader or any other person has a medical concern, he or she should consult with an appropriately-licensed physician or other legally accredited health care worker in the country that resides or is visiting.
Please do not delay your medical concerns and potential health emergencies by searching information in this website, instead look out for medical opinion in the services that exist with that specific purpose and work under the respective local health-care regulations.
The views expressed on this blog and website have no relation to those of any academic, hospital, practice or other institution with which the authors are affiliated.
For other instances, the authors of this website do not have any conflict of interest with any institution or pharmaceutical company in particular, and do not receive any compensation about any licenced drug mentioned in the website. In the same matter, the website is not intended to recommend any specific patented medication.
EMDrugs Team